Farydak (panobinostat) / Secura Bio 
Welcome,         Profile    Billing    Logout  
 197 Diseases   15 Trials   15 Trials   2024 News 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
CINC424A2X01B, NCT02386800 / 2014-003527-22: Rollover Protocol

Active, not recruiting
4
279
Europe, Canada, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27
2017-000764-15: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS

Ongoing
3
350
Europe
Farydak, Capsule, hard, Farydak
Universitätsklinikum Frankfurt, Novartis Pharma GmbH
High risk acute myeloid leukemia or myelodysplastic syndrome Hoch-risiko akute myeloische Leukämie oder myelodysplastisches Syndrom, Acute myeloid leukemia (AML). Myelodysplastic syndrome (MDS) Akute myeloische Leukämie (AML). Myelodysplastisches Syndrom (MDS)., Diseases [C] - Cancer [C04]
 
 
NCT04326764: Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Terminated
3
52
Europe
Panobinostat, Farydak
Goethe University, Stichting Hemato-Oncologie voor Volwassenen Nederland, Polish Adult Leukemia Group, Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
02/23
02/23
2010-018699-26: Study with panobinostat maintenance therapy following stem cell transplantation in patients with high risk Myelodysplastic Syndrome or Acute Myeloic Leukemia

Ongoing
2
62
Europe
Panobinostat, LBH 589, Capsule, hard
Goethe Universität Frankfurt, Novartis Pharma GmbH
MDS and AML in patients with high risk features after hemapoietic stem cell transplantation with reduced conditioning, Myelodyspastic Syndrome and Acute Myeloblastic Leukemia in patients with high risk features after stem cell transplantation with reduced conditioning, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2007-007939-29: A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.

Ongoing
2
42
Europe
Thalidomide, Thalidomide
FONDAZIONE NEOPLASIE SANGUE ONLUS
Patients with refractory or advanced Multiple Myeloma.
 
 
PANORAMA_3, NCT02654990 / 2015-001564-19: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed
2
248
Europe, Canada, US, RoW
Panobinostat Capsules, PAN, LBH589, Farydak, Bortezomib Injection, BTZ, Velcade, Dexamethasone tablets, Dex, Decadron
pharmaand GmbH, Novartis Pharma Services AG, Secura Bio, Inc.
Multiple Myeloma
10/19
08/22
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12618000321246: A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma.

Active, not recruiting
2
60
 
Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG), NHMRC
Osteosarcoma, Malignant Rhabdoid Tumour, Neuroblastoma, Atypical Teratoid/Rhabdoid Tumour (AT/RT)
 
 
2020-000382-16: Efficacy of daratumumab (Dara) retreatment of relapsed/ refractory multiple myeloma (RRMM) patients in combination with panobinostat, bortezomib-and dexamethasone Wirksamkeit einer wiederholten Daratumumab (Dara) Behandlung von Patienten mit rezidiviertem/refraktärem Multiplen Myelom (RRMM) in Kombination mit Panobinostat, Bortezomib und Dexamethason

Not yet recruiting
2
30
Europe
Darzalex, Farydak, Velcade, L01XC24, L01XX42, L01XX32, Concentrate for solution for injection, Capsule, hard, Powder for solution for injection, Daratumumab (DARZALEX® 1.800 mg Injektionslösung), Farydak (Panobinostat), Velcade (Bortezomib)
Medical Center - University of Freiburg, University of Freiburg, Faculty of Medicine, Janssen-Cilag GmbH
Relapsed and refractory multiple myeloma Rezidives und refraktäres Multiples Myelom, Relapsed and refractory multiple myeloma wiederkehrendes / therapieresistentes Multiples Myelom, Diseases [C] - Cancer [C04]
 
 
NCT02506959: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed
2
83
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Panobinostat, Faridak, LBH589, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
06/24
06/24
EVIDENT, NCT05725200: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
ACTRN12612000746831: A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Recruiting
1/2
30
 
Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Novartis Pharmaceuticals Australia Pty Limited
Relapsed and Refractory Indolent B-cell Lymphoma
 
 
2012-003344-74: A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AML

Ongoing
1/2
70
Europe
panobinostat, Dacogen, Dacogen
HOVON Foundation, Dutch Cancer Society, Novartis, Janssen Cilag, HOVON Foundation
(very) poor risk AML or RAEB with IPSS ≥ 1.5
 
 
2017-002335-42: A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation . Onderzoek naar de behandeling van patiënten met een specifiek type AML, met de middelen panobinstat en midostaurin gedurende 1 jaar na donor-stamceltransplantatie.

Ongoing
1/2
40
Europe
panobinostat, Midostaurin, Capsule, Farydak 20 mg, Rydapt
HOVON Foundation, Novartis
adverse risk AML or RAEB, 'High risk' acute myeloid leukemia of myedysplastic syndrome, Diseases [C] - Cancer [C04]
 
 
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
ORBIT, NCT06240520: Optimizing Reversal of HIV Latency With Combination Therapy

Not yet recruiting
1/2
49
Europe
Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, AIDSfonds
Hiv
05/25
10/25
ACTRN12609000185268: LBH589 in combination with External Beam Radiotherapy or Chemoradiation for Locally Advanced Non Small Cell Lung Cancer

Recruiting
1
30
 
Royal Adelaide Hospital, Novartis Pharmaceuticals Australia Pty Limited
Lung cancer
 
 
NCT02899715: Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma

Recruiting
1
30
US
Laboratory Biomarker Analysis, Panobinostat, Faridak, Farydak, LBH589, Pharmacological Study
National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma
10/19
 
NCT01301807: Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Completed
1
63
US
Carfilzomib, Kyprolis, PR-171, Panobinostat, Faridak, Farydak, LBH589
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
11/19
11/19
PBTC-047, NCT02717455: Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Completed
1
53
US
LBH589, Panobinostat
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI)
Glioma
02/22
03/24
NCT04804709: Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)

Active, not recruiting
1
3
US
Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
Cheng-Chia (Fred) Wu, Focused Ultrasound Foundation
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
12/23
12/25
DIPG, NCT04341311: Phase I Study of Marizomib + Panobinostat for Children With

Terminated
1
4
US
Marizomib, salinosporamide A, salinosporin A, Panobinostat, Farydak
Dana-Farber Cancer Institute, Celgene, Secura Bio, Inc.
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
02/24
02/24
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT01245179: Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Recruiting
1
18
US
panobinostat, LBH589, LBH589 lactate, FARYDAK®
Abdullah Kutlar, Secura Bio, Inc.
Sickle Cell Disease
12/25
03/26
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02568943 / 2014-003239-21: An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

No Longer Available
N/A
Europe, Canada, RoW
Panobinostat, LBH589
Novartis Pharmaceuticals
Multiple Myeloma
 
 
RECOMM, NCT04150289: A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Completed
N/A
248
US
Farydak
zr Pharma & GmbH
Multiple Myeloma
03/22
03/22
ChiCTR2000040627: Panobinostat Reverses HepaCAM Gene Expression and Suppresses Proliferation by Increasing Histone Acetylation in Urologic neoplasms

Completed
N/A
50
 
No Interventions
Chongqing Medical University; Chongqing Medical University, Natural Science Foundation of China
Urologic neoplasms
 
 

Download Options